Akèy › Myelom Miltip › Kentucky › Louisville
Etid klinik pou Myelom Miltip nan Louisville, KY
12 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Louisville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, Louisville
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Norton Cancer Institute, Louisville
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Norton Cancer Institute, Louisville
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Norton Cancer Institute, Louisville
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 3
- Norton Cancer Institute, Louisville
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Norton Healthcare, Inc., Louisville
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Norton Women's and Children's Hospital, Louisville
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, Louisville
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Ap rekriteFaz 1
- Norton Cancer Institute St. Matthews, Louisville
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Ap rekriteFaz 1/2
- Norton Cancer Institute, Louisville
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Norton Cancer Institute, Louisville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Baptist Floyd, New Albany · 4 mi lwen
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Louisville
- Kansè Poumon ki pa ti selil22 etid
- Obèsite17 etid
- Sipwa15 etid
- Kansè (tout kalite)14 etid
- Ensifizyans kadyak13 etid
- Leksemi mieloïd egi12 etid
- Kansè ovè12 etid
- Kansè poumon11 etid
- Kansè nan tete11 etid
- Karsinòm selil skuamèz tèt ak kou11 etid
- Kansè pwostat10 etid
- Kolit Ulseratif10 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.